Gossamer Bio, Inc.
NASDAQ:GOSSBiotechnology
+$0.01 today
- Market cap
- $67.52M
- Beta
- 2.04
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$0.77
Volume 0.22M
Average 19.76M
Returns on capital
Gossamer Bio, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
138.8%
avg -227.0%
ROIC
-148.7%
avg 35.3%
ROA
-98.9%
avg -213.6%
Analysis
ROE is currently the strongest return metric at 138.8% versus its period average of -227.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Faheem Hasnain | Co-Founder, Chief Executive Officer, President & Chairman | USD 908.45K | 68 | 166 | <0.01% |
Bryan Giraudo | Chief Operating Officer & Chief Financial Officer | USD 676.74K | 51 | 25 | <0.01% |
Robert Smith | Chief Commercial Officer | USD 663.71K | 57 | — | — |
Christian Waage | Executive Vice President, Technical Operations & General Counsel | USD 583.16K | 59 | 2.90M | 0.59% |
Kelly Dawson | Senior Vice President & Program Team Lead | — | — | — | — |
Jean-Marie Bruey | Senior Vice President of Translational Medicine & Research | — | — | — | — |
Caryn L. Peterson | Chief Development Officer | — | 67 | — | — |
Deanna Weber | Executive Vice President of Human Resources | — | — | — | — |
Jeanine Anthony | Senior Vice President of Marketing | — | — | — | — |
Robert F. Roscigno | Senior Vice President of Clinical Development of Pulmonary Vascular Disease | — | 60 | — | — |
Conor O'Donovan | Senior Vice President of Regulatory Affairs | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 18, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 24, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | +41.3% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Forward estimates point to Revenue at +41.3% (5yr), giving you a quick read on expected growth from here.
Competitors
Who does Gossamer Bio, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about GOSS's management, answered from reported figures.
Who manages GOSS?
Gossamer Bio, Inc. (GOSS) lists 11 active executives. The top listed executive is Kelly Dawson, Senior Vice President & Program Team Lead.
Are GOSS insiders buying or selling?
Recent insider activity shows net selling of $2.35M.
Continue the stock analysis
Jump to another research area for this company.